Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease [Phase 1]

View source ↗

Summary

Phase 1 trial update on PF-04447943 with/without hydroxyurea in stable sickle cell disease examining safety, tolerability, PK, and PD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• PF-04447943 (PF-04447943)

Snippet

Sponsor: Pfizer | Conditions: Phase 1 Sickle Cell | Phase 1 | Status: COMPLETED | Results posted: 2017-12-14